PRLD

Prelude Therapeutics Incorporated

Price

$5.78

return (12m)

547.11%

p/e

-8.80

p/bv

3.98

DIVIDEND YIELD

0.00%

PRLD price

Prelude Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PRLD

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

41.32%

3 months

33.49%

1 year

547.11%

2 years

-1.53%

5 years

-81.35%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals PRLD

Valuation

P/E

-8.80

Sector -4.38

Industry -4.38

P/BV

3.98

Sector 2.02

Industry 2.02

P/Revenue (PSR)

23.74

Sector -4.40

Industry -4.40

EV/EBITDA

-25.19

Sector -263.09

Industry -263.09

EV/EBIT

-24.62

Sector -702.90

Industry -702.90

P/EBITDA

-8.09

Sector -4.39

Industry -4.39

P/EBIT

-7.90

Sector -4.73

Industry -4.73

P/Total Assets

2.81

Sector 1.49

Industry 1.49

P/Net Current Assets

5.36

Sector -11.70

Industry -11.70

P/Working Capital

4.55

Sector -3.19

Industry -3.19

EPS

-0.62

Sector -2.14

Industry -2.14

BVPS

1.36

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

100.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-264.91%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-271.05%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.03

Sector 0.03

Industry 0.03

Profitability

ROE

-45.23%

Sector -65.14%

Industry -65.14%

ROA

-31.94%

Sector -65.53%

Industry -65.53%

ROIC

-88.73%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.07

Sector 2.90

Industry 2.90

Net Debt / EBITDA

10.05

Sector -6.07

Industry -6.07

Net Debt / EBIT

9.82

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.13

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.71

Sector 0.41

Industry 0.41

Liabilities/Assets

0.29

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-11.54%

Sector -

Industry -

Fundamentals PRLD

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PRLD Prelude Therapeutics Incorporated	$5.78	512.22%	0.00%	-8.80	3.98	-45.23%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PRLD Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Prelude Therapeutics

Prelude Therapeutics Incorporated

Average Investor10 user rating

4.0 (0 people)

United States

10 years

Founded: 2016

2020

Time since IPO - 6 years

51

Employees

Prelude Therapeutics Incorporated (United States) is listed on the Nasdaq and has a market capitalization of $532.14 million, with shareholders equity totaling $133.73 million.

The company employs approximately 51 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Prelude Therapeutics Incorporated reported $22.42 million in revenue, generating net income of $-60.49 million.

Key financial metrics include a P/E ratio of -8.80, a price-to-book (P/B) ratio of 3.98, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PRLD.

Market cap

$532.14 million

Net worth

$133.73 million

$133,730,000.00

Assets

$189.36 million

$189,360,000.00

Total Shares Outstanding

98.00 million

98,000,000

Average Daily Trading Volume

$452.46 Thousand

$452,463.98

Sector

Health Care

Industry

Biotechnology

PRLD

PRLD revenue and profits

Financial Results PRLD

DRAG THE FRAME TO SEE MORE DATA

PRLD cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Prelude Therapeutics (PRLD) today?

A cotação de Prelude Therapeutics (PRLD) hoje está em US$ 5.78, com uma variação de 547.11% em relação ao último ano. A cotação de Prelude Therapeutics (PRLD) iniciou o ano negociando na casa dos US$ 2.90 e hoje está em US$ 5.78. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Prelude Therapeutics (PRLD) e dados de ações do Ibovespa e mercados internacionais.

Quando Prelude Therapeutics (PRLD) paga dividendos?

Prelude Therapeutics (PRLD) não distribuiu dividendos no último ano.

Is Prelude Therapeutics (PRLD) a good investment?

Atualmente, Prelude Therapeutics (PRLD) está cotada a US$ 5.78, com um P/L de -8.80, representando um desvio de -332% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 547.11 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 547.11%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Prelude Therapeutics (PRLD) stock?

Investir em ações de Prelude Therapeutics (PRLD) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Prelude Therapeutics (PRLD) yield today?

A rentabilidade de Prelude Therapeutics (PRLD) foi de 41.32% no último mês, 547.11% no último ano e -81.35% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Prelude Therapeutics (PRLD) hoje, o investimento total seria de US$ 578.00, com base na cotação atual de US$ 5.78.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 3,740.30
Em 5 anos: US$ 107.80
Em 10 anos: US$ 578.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PRLD

Prelude Therapeutics Incorporated

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PRLD

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING PRLD WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Prelude Therapeutics

Prelude Therapeutics Incorporated

United States

10 years

2020

51

PROFIT X PRICE PRLD

Financial Results PRLD

PRLD cash flow

Asset, Revenue and Profit Growth - PRLD

PRLD balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions